Last reviewed · How we verify

Epilepsy having focal-onset seizures — Treatment Landscape & Competitive Intelligence

Epilepsy having focal-onset seizures (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Epilepsy having focal-onset seizures, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Xcopri CENOBAMATE Sk Life Gamma-aminobutyric acid receptor subunit alpha-4 2019-01-01
Xcopri Xcopri SK Life Science, Inc. Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. SK Life Science, Inc. · 1 drug in Epilepsy having focal-onset seizures
  2. Sk Life · 1 drug in Epilepsy having focal-onset seizures

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Epilepsy having focal-onset seizures:

Cite this brief

Drug Landscape (2026). Epilepsy having focal-onset seizures — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/epilepsy-having-focal-onset-seizures. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing